2022
TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs
Ball S, Loghavi S, Zeidan A. TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs. Leukemia & Lymphoma 2022, 64: 540-550. PMID: 36323304, DOI: 10.1080/10428194.2022.2136969.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaMyelodysplastic syndromeVariant allele frequencyMyeloid leukemiaMDS/acute myeloid leukemiaIndependent poor prognostic factorBCL2 inhibitor venetoclaxPoor prognostic factorDisease-modifying therapiesIntensive chemotherapyBlast countClinical coursePrognostic factorsInvestigational agentsDisease entityClinical studiesInhibitor venetoclaxMyeloid neoplasmsResponse ratePathogenic alterationsNeoplasmsDistinct genetic entitiesLeukemiaGenetic characteristicsAllele frequencies
2015
The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions
Lee EJ, Podoltsev N, Gore SD, Zeidan AM. The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions. Blood Reviews 2015, 30: 1-10. PMID: 26119927, DOI: 10.1016/j.blre.2015.06.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeRisk stratificationRecurrent molecular mutationsRisk stratification toolRelevant clinical outcomesPrediction of outcomeRisk/benefit calculationsClinical courseClinical outcomesStratification toolMDS patientsPrognostication toolsIndividual patientsClinical practiceMolecular testingTherapeutic interventionsPatient careTherapeutic selectionPatientsMolecular mutationsIndependent impactPrognosticationBiological heterogeneityOutcomesReliable assay